• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.达雷妥尤单抗对CD38的长期饱和作用会干扰骨髓瘤细胞的诊断检测。
Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.
2
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.达雷妥尤单抗耐药在晚期多发性骨髓瘤患者中很常见，与 CD38 表达无关，与预后不良有关。
Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.
3
Daratumumab in multiple myeloma.达雷妥尤单抗在多发性骨髓瘤中的应用。
Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5.
4
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.基于达雷妥尤单抗的化疗后多发性骨髓瘤患者出现CD38阴性复发
Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6.
5
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody.与血清抗 CD38 单克隆抗体水平升高相关的造血干细胞动员失败。
Eur J Haematol. 2023 Aug;111(2):318-321. doi: 10.1111/ejh.14008. Epub 2023 May 20.
6
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.达雷妥尤单抗增强了在模拟肿瘤微环境条件的生化环境中针对 CD38+多发性骨髓瘤细胞系的同种异体反应性自然杀伤细胞的细胞毒性。
Cancer Immunol Immunother. 2018 Jun;67(6):861-872. doi: 10.1007/s00262-018-2140-1. Epub 2018 Mar 2.
7
Loss of CD38 expression in myelomatous pleural effusion in a patient with myeloma treated with daratumumab: Report of a case.达雷妥尤单抗治疗的骨髓瘤患者出现骨髓瘤性胸腔积液中CD38表达缺失：一例报告
Diagn Cytopathol. 2021 Jan;49(1):168-170. doi: 10.1002/dc.24630. Epub 2020 Oct 1.
8
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.CD38 表达和补体抑制剂影响多发性骨髓瘤患者对达雷妥尤单抗治疗的反应和耐药性。
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.
9
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.DNA甲基转移酶抑制剂上调CD38蛋白表达并增强达雷妥尤单抗在多发性骨髓瘤中的疗效。
Leukemia. 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
10
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.VS38 鉴定出在达雷妥尤单抗治疗后 CD38 弱表达的骨髓瘤细胞和浆细胞，这会干扰 CD38 检测达 4 至 6 个月。
Am J Clin Pathol. 2020 Jan 2;153(2):221-228. doi: 10.1093/ajcp/aqz153.

引用本文的文献

1
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy.将微小残留病阴性作为多发性骨髓瘤治疗的主要目标。
Drugs. 2025 Sep 4. doi: 10.1007/s40265-025-02232-7.
2
Assembly and performance of a cholera RDT prototype that detects both and associated bacteriophage as a proxy for pathogen detection.一种霍乱快速诊断检测原型的组装与性能，该原型可同时检测霍乱弧菌及相关噬菌体以作为病原体检测的替代指标。
J Clin Microbiol. 2025 Feb 19;63(2):e0144324. doi: 10.1128/jcm.01443-24. Epub 2024 Dec 31.
3
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.靶向BCMA的微小残留病检测作为多发性骨髓瘤中BCMA嵌合抗原受体T细胞治疗后复发的预测指标
Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):52-57. doi: 10.1016/j.clml.2024.10.003. Epub 2024 Oct 11.
4
Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers.数学建模揭示了血液癌症靶向放射性核素治疗的优化策略。
Cancer Res Commun. 2024 Nov 1;4(11):2955-2967. doi: 10.1158/2767-9764.CRC-24-0306.
5
[Chinese expert consensus on the application of flow cytometry for the detectin of circulating plasma cells in plasma cell disorders (2024)].《流式细胞术检测浆细胞疾病循环血浆细胞的应用中国专家共识（2024年）》
Zhonghua Xue Ye Xue Za Zhi. 2024 Apr 14;45(4):313-321. doi: 10.3760/cma.j.cn121090-20240117-00026.
6
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.裸抗体和抗体药物偶联物：儿童急性淋巴细胞白血病的靶向治疗。
Haematologica. 2024 Jun 1;109(6):1700-1712. doi: 10.3324/haematol.2023.283815.
7
Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers.数学建模揭示了血液癌症靶向放射性核素治疗的优化策略。
bioRxiv. 2024 May 23:2024.05.22.595377. doi: 10.1101/2024.05.22.595377.
8
Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma.抗 CD38 与检查点抑制剂治疗 NK/T 细胞淋巴瘤的不良反应。
Front Immunol. 2024 Apr 12;15:1346178. doi: 10.3389/fimmu.2024.1346178. eCollection 2024.
9
Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma.获得性CD38基因缺失作为多发性骨髓瘤中肿瘤抗原逃逸的一种机制。
Blood Adv. 2023 Dec 12;7(23):7235-7238. doi: 10.1182/bloodadvances.2023011295.
10
B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses.B 细胞靶向治疗抗 CD38 达雷妥尤单抗：对分化和记忆应答的影响。
Life Sci Alliance. 2023 Jul 7;6(9). doi: 10.26508/lsa.202302214. Print 2023 Sep.

本文引用的文献

1
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
2
Immunotherapies targeting CD38 in Multiple Myeloma.靶向多发性骨髓瘤中CD38的免疫疗法。
Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016.
3
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.在先前接受蛋白酶体抑制剂和免疫调节药物治疗的复发或难治性多发性骨髓瘤患者中，达雷妥尤单抗静脉输注后的药代动力学。
Clin Pharmacokinet. 2017 Aug;56(8):915-924. doi: 10.1007/s40262-016-0477-1.
4
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者剂量方案的复杂药代动力学的临床意义
Clin Pharmacol Ther. 2017 Jun;101(6):721-724. doi: 10.1002/cpt.577. Epub 2017 Feb 13.
5
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.达雷妥尤单抗单克隆抗体对游离轻链检测干扰的研究。
Clin Biochem. 2016 Oct;49(15):1202-1204. doi: 10.1016/j.clinbiochem.2016.07.016. Epub 2016 Jul 28.
6
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.CD38 表达和补体抑制剂影响多发性骨髓瘤患者对达雷妥尤单抗治疗的反应和耐药性。
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.
7
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.达雷妥尤单抗单药治疗在多次预处理的复发或难治性多发性骨髓瘤患者中的临床疗效。
Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.
8
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.达雷妥尤单抗，一种新型 CD38 单克隆抗体，在骨髓瘤中的应用的实际考虑。
Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4.
9
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).达雷妥尤单抗会干扰多发性骨髓瘤患者的血清免疫固定电泳监测，使用达雷妥尤单抗免疫固定电泳反射检测（DIRA）可消除这种干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1105-9. doi: 10.1515/cclm-2015-0888.
10
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

作者信息

Oberle Anna, Brandt Anna, Alawi Malik, Langebrake Claudia, Janjetovic Snjezana, Wolschke Christine, Schütze Kerstin, Bannas Peter, Kröger Nicolaus, Koch-Nolte Friedrich, Bokemeyer Carsten, Binder Mascha

机构信息

Department of Oncology and Hematology, Hubertus Wald Tumorzentrum, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Bioinformatics Core, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18.

DOI:10.3324/haematol.2017.169235
PMID:28522580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5685239/
Abstract
摘要